लोड हो रहा है...
Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib...
में बचाया:
| में प्रकाशित: | Clin Case Rep |
|---|---|
| मुख्य लेखकों: | , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
John Wiley and Sons Inc.
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5224778/ https://ncbi.nlm.nih.gov/pubmed/28096995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.749 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|